Quetiapine (ICI-204636) fumarate

Catalog No.S1763

For research use only.

Quetiapine Fumarate (ICI-204636) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression and shows affinity for various neurotransmitter receptors including serotonin, dopamine, histamine, and adrenergic receptors.

Quetiapine (ICI-204636) fumarate Chemical Structure

CAS No. 111974-72-2

Selleck's Quetiapine (ICI-204636) fumarate has been cited by 3 Publications

Purity & Quality Control

Choose Selective Dopamine Receptor Inhibitors

Other Dopamine Receptor Products

Biological Activity

Description Quetiapine Fumarate (ICI-204636) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression and shows affinity for various neurotransmitter receptors including serotonin, dopamine, histamine, and adrenergic receptors.
Targets
Dopamine receptor [1] Histamine receptor [1] Adrenergic Receptor [1]
In vitro

Quetiapine shows affinity for various neurotransmitter receptors including serotonin, dopamine, histamine, and adrenergic receptors and has binding characteristics at the dopamine-2 receptor similar to those of clozapine. [1]

In vivo Quetiapine has a preclinical profile suggestive of antipsychotic activity with a reduced tendency to cause extrapyramidal symptoms (EPS) and sustained prolactin elevation. Guetiapine alters neurotensin neurotransmission and c-fos expression in limbic but not motor brain regions. Quetiapine also demonstrates clozapine-like activity in a range of behavioral and biochemical tests and may possess neuroprotective properties. [1] Quetiapine dose-dependently prevents schizophrenia and depression in hippocampal cell proliferation and BDNF expression caused by chronic restraint stress (CRS) in rats. Guetiapine (5 mg/kg) combined with Venlafaxine (2.5 mg/kg) increases hippocampal cell proliferation and prevents BDNF decrease in stressed rats, whereas each of the drugs exerts mild or no effects. [2] Guetiapine produces selective effects on cortical and limbic regions of the brain and in particular on dopaminergic neurotransmission in these regions. Guetiapine produces lower levels of putamenal DA D2r occupancy than those reported for typical APDs. Quetiapine also produces preferential occupancy of temporal cortical DA D2r, 46.9%, but does not spare occupancy of substantia nigra DA D2r. [3] Guetiapine attenuates the decrease in levels of brain-derived neurotrophic factor (BDNF) in the hippocampi of rats subjected to chronic-restraint stress. Guetiapine (10 mg/kg) reverses the stress-induced suppression of hippocampal neurogenesis, evidenced in the numbers of BrdU-labeled and pCREB-positive cells that are comparable to those in non-stressed rats but higher than those in the vehicle-treated rats. [4]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 36 mg/mL
(40.76 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
0.5% CMC Na
For best results, use promptly after mixing.

30mg/mL

Chemical Information

Molecular Weight 883.09
Formula

C46H54N6O8S2

CAS No. 111974-72-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=CC(=O)O)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00837343 Unknown status Drug: quetiapine fumarate tablet (Seroquel) Bipolar Disorder Guangzhou Mental Hospital|First Affiliated Hospital of Jinan University|Second Affiliated Hospital of Guangzhou Medical University|Guangzhou mental Hospital Attached to Guangzhou Civil Affairs Bureau December 2008 Phase 4
NCT00838032 Unknown status Drug: Quetiapine fumarate|Drug: Haloperidol Acute Schizophrenia Sichuan University August 2008 Phase 4
NCT00631722 Completed Drug: Quatiapine Fumarate|Drug: Haloperidol Schizophrenia Peking University May 2007 Not Applicable
NCT00448578 Completed Drug: Quetiapine Fumarate|Drug: Lithium Mania|Bipolar Disorder AstraZeneca August 2005 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I want to know if your recommended formulation for in vivo experiments on the website is suitable for oral administration or injection?

Answer:
S1763 Quetiapine Fumarate can be dissolved in 0.5% CMC Na at 30 mg/ml as a suspension. It is fine for oral gavage.

Tags: buy Quetiapine (ICI-204636) fumarate | Quetiapine (ICI-204636) fumarate ic50 | Quetiapine (ICI-204636) fumarate price | Quetiapine (ICI-204636) fumarate cost | Quetiapine (ICI-204636) fumarate solubility dmso | Quetiapine (ICI-204636) fumarate purchase | Quetiapine (ICI-204636) fumarate manufacturer | Quetiapine (ICI-204636) fumarate research buy | Quetiapine (ICI-204636) fumarate order | Quetiapine (ICI-204636) fumarate mouse | Quetiapine (ICI-204636) fumarate chemical structure | Quetiapine (ICI-204636) fumarate mw | Quetiapine (ICI-204636) fumarate molecular weight | Quetiapine (ICI-204636) fumarate datasheet | Quetiapine (ICI-204636) fumarate supplier | Quetiapine (ICI-204636) fumarate in vitro | Quetiapine (ICI-204636) fumarate cell line | Quetiapine (ICI-204636) fumarate concentration | Quetiapine (ICI-204636) fumarate nmr